AU2013259393B2 - V1a receptor agonists - Google Patents

V1a receptor agonists Download PDF

Info

Publication number: AU2013259393B2
Authority: AU; Australia
Prior art keywords: compound; hydrogen; substituted; alkylene; aryl
Prior art date: 2012-05-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

AU2013259393A

Other languages

English (en)

Other versions

AU2013259393A1 (en

Inventor

Robert Felix Galyean

Geoffrey S. HARRIS

Kazimierz Wisniewski

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Ferring BV

Original Assignee

Ferring BV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-05-10

Filing date

2013-05-09

Publication date

2017-02-02

2013-05-09 Application filed by Ferring BV filed Critical Ferring BV

2014-11-20 Publication of AU2013259393A1 publication Critical patent/AU2013259393A1/en

2015-04-09 Assigned to FERRING B.V. reassignment FERRING B.V. Request for Assignment Assignors: FERRING B.V., WISNIEWSKI, KAZIMIERZ

2017-02-02 Application granted granted Critical

2017-02-02 Publication of AU2013259393B2 publication Critical patent/AU2013259393B2/en

Status Active legal-status Critical Current

2033-05-09 Anticipated expiration legal-status Critical

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Diabetes (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Plural Heterocyclic Compounds (AREA)
Polyurethanes Or Polyureas (AREA)
Polyesters Or Polycarbonates (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

AU2013259393A 2012-05-10 2013-05-09 V1a receptor agonists Active AU2013259393B2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261645558P	2012-05-10	2012-05-10
US61/645,558		2012-05-10
PCT/US2013/040414 WO2013170077A2 (en)	2012-05-10	2013-05-09	V1a receptor agonists

Publications (2)

Publication Number	Publication Date
AU2013259393A1 AU2013259393A1 (en)	2014-11-20
AU2013259393B2 true AU2013259393B2 (en)	2017-02-02

Family

ID=48652296

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2013259393A Active AU2013259393B2 (en)	2012-05-10	2013-05-09	V1a receptor agonists

Country Status (28)

Country	Link
US (1)	US9644000B2 (sr)
EP (1)	EP2847210B1 (sr)
JP (1)	JP6231554B2 (sr)
KR (1)	KR102050356B1 (sr)
CN (1)	CN104350065B (sr)
AR (1)	AR091013A1 (sr)
AU (1)	AU2013259393B2 (sr)
BR (1)	BR112014027996B1 (sr)
CA (1)	CA2871776C (sr)
DK (1)	DK2847210T3 (sr)
ES (1)	ES2571928T3 (sr)
HR (1)	HRP20160468T1 (sr)
HU (1)	HUE027519T2 (sr)
IL (1)	IL235558A (sr)
JO (1)	JO3109B1 (sr)
MX (1)	MX353864B (sr)
MY (1)	MY167248A (sr)
NZ (1)	NZ701365A (sr)
PH (1)	PH12014502510A1 (sr)
PL (1)	PL2847210T3 (sr)
RS (1)	RS54722B1 (sr)
RU (1)	RU2634617C2 (sr)
SA (1)	SA113340536B1 (sr)
SG (1)	SG11201407400XA (sr)
SI (1)	SI2847210T1 (sr)
TW (1)	TWI632161B (sr)
WO (1)	WO2013170077A2 (sr)
ZA (1)	ZA201408172B (sr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9388214B2 (en)	2014-11-05	2016-07-12	Ferring B.V.	V1A receptor agonists
JP2017014206A (ja) *	2015-06-30	2017-01-19	ナノアンティバイオティクス，インコーポレイテッド	腹水の治療
US11021514B2 (en)	2016-06-01	2021-06-01	Athira Pharma, Inc.	Compounds
CN109010795B (zh) *	2018-09-12	2021-10-22	南京康舟医药科技有限公司	醋酸特利加压素注射液以及其制备方法
AU2020279395B2 (en)	2019-05-22	2025-08-28	Biovie Inc.	Formulations of terlipressin
PH12023550152A1 (en) *	2020-07-17	2024-03-18	Pharmain Corp	V1a receptor partial agonist and method of use
WO2023183339A1 (en) *	2022-03-22	2023-09-28	Ocelot Bio, Inc.	Selective vasopressin receptor agonist for end-stage liver disease
CN120265305A (zh) *	2022-09-30	2025-07-04	辉凌公司	治疗终末期肝病及其相关并发症的混合型血管加压素受体激动剂-拮抗剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1188443A1 (en) *	2000-09-15	2002-03-20	Ferring BV	Improved protocol for paracentesis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2003513082A (ja) *	1999-11-04	2003-04-08	オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド	バソプレッシン拮抗物質としての非ペプチド置換されたベンゾチアゼピン類
JO2937B1 (en) *	2004-08-11	2016-03-15	فيرينغ.بي.في	Tight muscles of the peptide vascular tensioner receptor
CA2615726C (en) *	2005-07-14	2014-05-27	Caterina Bissantz	Indol-3-yl-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists
KR101018934B1 (ko) *	2005-09-28	2011-03-02	에프. 호프만-라 로슈 아게	바소프레신 수용체 길항물질로서인돌-3-일-카보닐-아자스피로 유도체
DK1984012T3 (en) *	2006-02-13	2016-03-29	Ferring Bv	USE OF peptidic vasopressin receptor agonists
US7960336B2 (en) *	2007-08-03	2011-06-14	Pharmain Corporation	Composition for long-acting peptide analogs

2013
- 2013-04-24 JO JOP/2013/0118A patent/JO3109B1/ar active
- 2013-04-30 TW TW102115416A patent/TWI632161B/zh active
- 2013-05-08 SA SA113340536A patent/SA113340536B1/ar unknown
- 2013-05-09 WO PCT/US2013/040414 patent/WO2013170077A2/en not_active Ceased
- 2013-05-09 KR KR1020147034501A patent/KR102050356B1/ko active Active
- 2013-05-09 SG SG11201407400XA patent/SG11201407400XA/en unknown
- 2013-05-09 RU RU2014143941A patent/RU2634617C2/ru active
- 2013-05-09 SI SI201330175A patent/SI2847210T1/sl unknown
- 2013-05-09 BR BR112014027996-9A patent/BR112014027996B1/pt active IP Right Grant
- 2013-05-09 ES ES13729826T patent/ES2571928T3/es active Active
- 2013-05-09 NZ NZ701365A patent/NZ701365A/en unknown
- 2013-05-09 DK DK13729826.1T patent/DK2847210T3/en active
- 2013-05-09 PL PL13729826T patent/PL2847210T3/pl unknown
- 2013-05-09 JP JP2015511718A patent/JP6231554B2/ja active Active
- 2013-05-09 US US14/400,282 patent/US9644000B2/en active Active
- 2013-05-09 MY MYPI2014703280A patent/MY167248A/en unknown
- 2013-05-09 HR HRP20160468TT patent/HRP20160468T1/hr unknown
- 2013-05-09 EP EP13729826.1A patent/EP2847210B1/en active Active
- 2013-05-09 MX MX2014013646A patent/MX353864B/es active IP Right Grant
- 2013-05-09 AU AU2013259393A patent/AU2013259393B2/en active Active
- 2013-05-09 RS RS20160293A patent/RS54722B1/sr unknown
- 2013-05-09 CA CA2871776A patent/CA2871776C/en active Active
- 2013-05-09 CN CN201380024444.2A patent/CN104350065B/zh active Active
- 2013-05-09 HU HUE13729826A patent/HUE027519T2/en unknown
- 2013-05-10 AR ARP130101626 patent/AR091013A1/es active IP Right Grant
2014
- 2014-11-06 IL IL235558A patent/IL235558A/en active IP Right Grant
- 2014-11-07 ZA ZA2014/08172A patent/ZA201408172B/en unknown
- 2014-11-10 PH PH12014502510A patent/PH12014502510A1/en unknown

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1188443A1 (en) *	2000-09-15	2002-03-20	Ferring BV	Improved protocol for paracentesis

Also Published As

Publication number	Publication date
TWI632161B (zh)	2018-08-11
HUE027519T2 (en)	2016-10-28
RU2634617C2 (ru)	2017-11-02
US20150126432A1 (en)	2015-05-07
JO3109B1 (ar)	2017-09-20
PH12014502510B1 (en)	2014-12-22
MX2014013646A (es)	2015-03-03
AU2013259393A1 (en)	2014-11-20
SG11201407400XA (en)	2014-12-30
ZA201408172B (en)	2015-12-23
ES2571928T3 (es)	2016-05-27
TW201348262A (zh)	2013-12-01
AR091013A1 (es)	2014-12-30
HK1205706A1 (zh)	2015-12-24
EP2847210A2 (en)	2015-03-18
KR20150008175A (ko)	2015-01-21
US9644000B2 (en)	2017-05-09
MY167248A (en)	2018-08-14
CN104350065B (zh)	2020-04-28
WO2013170077A2 (en)	2013-11-14
MX353864B (es)	2018-02-01
CA2871776C (en)	2021-09-07
CN104350065A (zh)	2015-02-11
CA2871776A1 (en)	2013-11-14
PH12014502510A1 (en)	2014-12-22
DK2847210T3 (en)	2016-05-02
HRP20160468T1 (hr)	2016-06-03
WO2013170077A3 (en)	2014-03-27
RU2014143941A (ru)	2016-07-10
JP2015518820A (ja)	2015-07-06
SI2847210T1 (sl)	2016-06-30
PL2847210T3 (pl)	2016-08-31
SA113340536B1 (ar)	2015-10-08
RS54722B1 (sr)	2016-08-31
BR112014027996B1 (pt)	2021-07-27
IL235558A0 (en)	2015-01-29
BR112014027996A2 (pt)	2017-07-25
IL235558A (en)	2017-07-31
KR102050356B1 (ko)	2019-11-29
JP6231554B2 (ja)	2017-11-15
NZ701365A (en)	2016-05-27
EP2847210B1 (en)	2016-02-17

Legal Events

Date

Code

Title

Description

2015-04-09

PC1

Assignment before grant (sect. 113)

Owner name: FERRING B.V.

Free format text: FORMER APPLICANT(S): FERRING B.V.; WISNIEWSKI, KAZIMIERZ

2017-06-01

FGA

Letters patent sealed or granted (standard patent)

Publication	Publication Date	Title
AU2013259393B2 (en)	2017-02-02	V1a receptor agonists
US9388214B2 (en)	2016-07-12	V1A receptor agonists
JP6934011B2 (ja)	2021-09-08	Ｔｈｒｏｍｂｏｓｐｏｎｄｉｎ１結合ペプチド
TW201332573A (zh)	2013-08-16	腎上腺髓素之聚乙二醇基底前藥及其用途
KR102258630B1 (ko)	2021-05-28	펩티드-올리고우레아 키메라 화합물 및 이의 사용 방법
ES2366702T3 (es)	2011-10-24	Agonistas peptídicos de receptores de vasopresina.
EP3138851A1 (en)	2017-03-08	Quaternary assemblies of water-soluble non-peptide helical foldamers, their use and production thereof
NO854645L (no)	1986-05-22	Fremgangsmaate for fremstilling av basiske cykliske peptider.
US20230041996A1 (en)	2023-02-09	Calcium-sensing receptor agonist compound and application thereof
HK1205706B (en)	2016-09-15	V1a receptor agonists
CN101190942A (zh)	2008-06-04	具有溶血栓活性的化合物、其制备方法和应用
CN111170927B (zh)	2020-08-04	一种沙格列汀中间体的制备方法
WO2024260421A1 (zh)	2024-12-26	一种类肽化合物及其配合物、药物组合物和应用
AU2024311042A1 (en)	2026-02-05	Polypeptide conjugate, pharmaceutical composition containing polypeptide conjugate and use thereof
HK40052155B (zh)	2024-12-20	二聚的肽-磷脂缀合物的优化方法
CN102153623A (zh)	2011-08-17	具有溶血栓活性的化合物、其制备方法和应用